about
Resveratrol amplifies profibrogenic effects of free fatty acids on human hepatic stellate cellsThe interaction of hepatic lipid and glucose metabolism in liver diseasesMacrophage Depletion Attenuates Extracellular Matrix Deposition and Ductular Reaction in a Mouse Model of Chronic CholangiopathiesNASH Cirrhosis - the New Burden in Liver Transplantation: How Should It Be Managed?NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLDNon-invasive separation of alcoholic and non-alcoholic liver disease with predictive modelingLow levels of blood lipids are associated with etiology and lethal outcome in acute liver failureAdipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients.Effects of Bariatric Surgery on Non-alcoholic Fatty Liver Disease: Magnetic Resonance Imaging Is an Effective, Non-invasive Method to Evaluate Changes in the Liver Fat Fraction.[Arrhythmogenic right ventricular cardiomyopathy mimicking right ventricular outflow tract tachycardia].Acid sphingomyelinase deficiency in Western diet-fed mice protects against adipocyte hypertrophy and diet-induced liver steatosis.Partial spleen embolization reduces the risk of portal hypertension-induced upper gastrointestinal bleeding in patients not eligible for TIPS implantationBioelectrical impedance analysis in clinical practice: implications for hepatitis C therapy BIA and hepatitis C.Behavioral conditioning of immunosuppression is possible in humans.Identification of novel biomarker candidates for the immunohistochemical diagnosis of cholangiocellular carcinoma.From NAFLD to NASH to cirrhosis-new insights into disease mechanisms.Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases.Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome.Serum sodium based modification of the MELD does not improve prediction of outcome in acute liver failureA non-interventional study of the genetic polymorphisms of NOD2 associated with increased mortality in non-alcoholic liver transplant patients.Evaluation of Biomarkers of NAFLD in a Cohort of Morbidly Obese Patients.NLRP3 inflammasome activation is required for fibrosis development in NAFLD.Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome.Acute liver failure: a life-threatening disease.Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant.Apoptosis: the nexus of liver injury and fibrosis.Higher Thyroid-Stimulating Hormone, Triiodothyronine and Thyroxine Values Are Associated with Better Outcome in Acute Liver Failure.All-In-One: Advanced preparation of Human Parenchymal and Non-Parenchymal Liver CellsOsteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in miceNormal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort.When the heart kills the liver: acute liver failure in congestive heart failureBathing in carbon dioxide-enriched water alters protein expression in keratinocytes of skin tissue in rats.Gallbladder endometriosis as a cause of occult bleeding.Apoptosis and fibrosis in non-alcoholic fatty liver disease.Impact of Liver Indicators on Clinical Outcome in Patients Undergoing Transcatheter Aortic Valve Implantation.Comparison of the sixth and the seventh editions of the UICC classification for perihilar cholangiocarcinomaIn Acute Myocardial Infarction Liver Parameters Are Associated With Stenosis Diameter.Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis.Lipid metabolism in the liver.Human Ex-Vivo Liver Model for Acetaminophen-induced Liver Damage.
P50
Q24626209-0E43DF16-0787-412E-A7AC-762E41C1CE42Q26827770-4C6F9051-2BF0-45B9-BD77-C4EE26EA40CAQ27324010-0D282F07-7AA8-411C-8CD2-74B18262520DQ28079900-0765774A-488A-4DD3-89D8-E5390B52DC0DQ28488938-4AA714AF-4390-4549-AE34-8D766E395DF0Q28540257-CAF0BFC2-E356-447A-B4E7-E23EB78E08DDQ28540768-75E020B2-B034-4295-91F5-E177487AAA60Q30367298-4E107ADC-5527-43DE-BCE7-C30840B268A4Q31153508-672CEDF5-6C47-492B-A586-DC72C300F42DQ33158446-F5F5936D-1418-4CBB-8FD5-E5746D31F249Q33600495-EAED50A8-FFCC-4855-ACB6-F98BD27CB4CEQ33664268-D2BC80DE-1A7F-41AD-9DE9-AEC272D941A8Q34094106-AE07ACF8-2509-4EB7-9734-71F166ED592CQ34162949-40BF222F-8331-49D2-9129-53F95D9C0695Q34303381-D73B0E3B-7C63-41A3-8E0C-FF4DEA9EFA66Q34365079-37B7EAE5-8A9D-484E-B1F6-1717690F0994Q34406470-491F59ED-0940-44BE-B121-10E5748C5C58Q34601701-FA0FE534-31EF-4067-A756-C9CCD88A95F6Q34646645-7B765892-FFA0-4D70-9FA1-81C53F40C005Q35083791-9D01EE68-1FD5-4AFE-A718-7ACA323F2BF3Q35101419-11EAFBF7-B2B9-4430-851F-E31FCF46E8F7Q35146713-00EDCBB5-D9E3-40A3-8402-41C29A23008BQ35250192-6D15C905-40BC-4CA0-A022-25B4BDFEC0F9Q35565411-1DAD91CB-34CE-414F-AC1A-1EEC02F9E510Q35626794-470052BB-72F4-407D-B811-BB29208BD74EQ35651666-B13B6663-54DD-4853-9726-EBC87FD4B224Q35684045-FE5FD442-29A5-4482-9A4F-28294C96C4E3Q35788567-94A2FF45-1B0B-42C4-8327-322FAA0C07F4Q35805769-768C91E1-1807-42AF-824B-B4A4461E9EA7Q35948791-7325AB5A-05AC-40CC-8898-B83954BAE781Q35958913-7675EDDE-E690-42FD-BB47-CA3F44149D32Q36154628-A5AD7EAC-78AC-4176-B9D7-F0AAB58CFAE5Q36179103-6DA3F5E5-22E2-4182-8564-E26DE9E55ED0Q36298426-B41EA742-635C-4D38-AE3A-DC65944B79C4Q36391815-8685D8C5-BE38-4385-82C9-DF14C49C2EEEQ36484946-2FC28CE1-3B10-4DBB-ACAB-E1CAFAF8F72DQ36581177-8ED9E482-7AEA-4620-93ED-465F3F509E40Q36588292-311C5B0D-1F9E-43F2-9CE9-55FD0196CD3FQ36712398-B7866988-B41F-420F-B825-5DADEDD332ECQ37195557-E7757A91-0112-4488-B3B0-EB1776070B2D
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ali Canbay
@ast
Ali Canbay
@en
Ali Canbay
@es
Ali Canbay
@nl
type
label
Ali Canbay
@ast
Ali Canbay
@en
Ali Canbay
@es
Ali Canbay
@nl
prefLabel
Ali Canbay
@ast
Ali Canbay
@en
Ali Canbay
@es
Ali Canbay
@nl
P214
P106
P214
P31
P496
0000-0001-6069-7899
P7859
lccn-n2019182137